Statin therapy in the secondary prevention of cerebrovascular events: Is it really beneficial in clinical practice?

Medical Hypotheses

Volumn 74, Issue 2, 2010, Pages 398-

  Mascitelli, Luca ^a   Pezzetta, Francesca ^b   Goldstein, Mark R ^c  

^a Medical Service ^*  (Italy)

^b Ospedale Civile di Tolmezzo   (Italy)

^c Fountain Medical Court ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADVERSE OUTCOME; AGE DISTRIBUTION; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG MEGADOSE; FATALITY; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LETTER; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SECONDARY PREVENTION; SURVIVAL RATE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COMORBIDITY; DRUG TOXICITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; STROKE; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 72649083665     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.08.010     Document Type: Letter

References (9)

1. Amarenco P., Bogousslavsky J., Callahan III A., et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
2. Mascitelli L., and Pezzetta F. Statin therapy after stroke or transient ischemic attack. N Engl J Med 355 (2006) 2369-2370
3. Amarenco P, Bogousslavsky J, Callahan AS, et al. SPARCL investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovas Dis 2003;16:389-95 [Erratum in: Cerebrovas Dis 2004;17:91-92.].
4. Feigin V.L., Lawes C.M., Bennett D.A., and Anderson C.S. Stroke epidemiology: a review of population based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2 (2003) 43-53
5. Townend E., Tinson D., Kwan J., and Sharpe M. Fear of recurrence and beliefs about preventing recurrence in persons who have suffered a stroke. J Psychosom Res 61 (2006) 747-755
6. Goldstein L.B., Amarenco P., Lamonte M., et al. On behalf of the SPARCL investigators. Relative effects of statin therapy on stroke and cardiovascular events in men and women. Secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Stroke 39 (2008) 2444-2448
7. Chaturvedi S., Zivin J., Breazna A., et al. For the SPARCL investigators. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 72 (2009) 688-694
8. Sillesen H., Amarenco P., Hennerici M.G., et al. On behalf of the SPARCL investigators. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis. A secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke 39 (2008) 3297-3302
9. Kent D.M., and Thaler D.E. Stroke prevention - insights from incoherence. N Engl J Med 359 (2008) 1287-1289